Picture BIO Deutschland Corona Special Germany 2020 650x80px
Product › Details

CentoMetabolic™ panel test for rare genetic metabolic diseases

Products Next higher product group clinical genomic test (nucleic acid diagnostics)_o
Period Status 2019-04-10 sales start
Organisation Organisation Centogene AG
  Group Centogene (Group)

Centogene AG. (4/10/19). "Press Release: Centogene Launches CentoMetabolic Panel for Integrated Multiomic Testing for Metabolic Diseases". Rostock & Berlin.

Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions

CENTOGENE today announced the launch of CentoMetabolic™, a first-line test for the widest range of rare genetic metabolic diseases. By combining genetic and biochemical testing, CentoMetabolic™ allows for immediate confirmation, and for many diagnoses a better understanding of the course of the disease, enhanced treatment monitoring, and tailored treatment guidance.

The differential diagnosis of a suspected genetic disorder often requires the analysis of multiple genes, for example conditions that show similar or overlapping phenotypes. CentoMetabolic™ includes as many as 166 genes. The panel was developed specifically for patients suspected to have a metabolic disorder or presenting complex, overlapping symptoms, a metabolic crisis or neurological conditions of unknown etiology. CentoMetabolic™ provides short turn-around-times targeting critically ill patients, and includes enzyme-activity testing where applicable, and a proprietary selection of biomarkers that is continually updated.

"The introduction of CentoMetabolic™ is a natural extension of our global knowledge and expertise, as it provides physicians and their patients with the confidence that they are receiving an accurate diagnosis of their suspected genetic metabolic condition," said Dr. Arndt Rolfs, CEO and founder of CENTOGENE. "Our rapid testing coupled with our unparalleled experience in metabolic disease genetics may put patients on the path to more immediate medical management, in particular in NICU or PICU, which is at the heart of CENTOGENE – reducing patients' diagnostic odyssey and creating new hope for our patients and their families."


CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity, and our innovative biomarkers.

As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for our patients with rare diseases and their families.



Ross Bethell
Director, Corporate Communications

Record changed: 2019-04-15


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for clinical genomic test (nucleic acid diagnostics)_o

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top